Everolimus [EVE7]
The treatment of unresectable or metastatic neuroendocrine tumours of gastrointestinal or lung origin with disease progression where all the following criteria are met:
- An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- The patient has histopathologically proven well differentiated neuroendocrine tumour of gastrointestinal or lung origin
- The patient has unresectable or metastatic disease
- The patient has no history of and no active symptoms to suggest a functional tumour
- The patient has exhibited disease progression in past 12 months
- The patient has a performance status of 0-1
NHS funded From: 26 September 2017
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.